Spondyloarthritis News and Research

RSS

Tryptophan digestion by gut microbiome spurs arthritis inflammation

A University of Colorado Department of Medicine faculty member says she and her colleagues have identified the means in which bacteria in the digestive system can break down tryptophan in the diet into an inflammatory chemical that primes the immune system towards arthritis.

7 Mar 2024

Unlocking sulfasalazine's mechanism of action in IBD-SpA patients

Although it is one of the oldest medications used to treat patients with inflammatory bowel disease (IBD) and an effective treatment for an associated arthritis condition called spondyloarthritis (SpA), sulfasalazine's mechanism of action has been unclear.

20 Feb 2024

Study shows nuanced pregnancy outcomes for pregnant individuals with autoimmune disease

For many aspiring mothers with autoimmune disease, pregnancy can be daunting and full of unknowns. In some cases, those suffering from specific autoimmune conditions have chosen to forego pregnancy altogether due to concerns about their disease treatments and adverse pregnancy outcomes.

1 Feb 2024

Study finds no fertility decline in men with inflammatory joint disease

Men with inflammatory joint disease, such as rheumatoid arthritis, are less likely to be childless and have more children than their healthy peers, suggests research published online in the Annals of the Rheumatic Diseases.

22 Jan 2024

New training program expands access to rheumatology care for Native American communities

New research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, describes the expansion of a novel program to train primary care physicians (PCPs) in the diagnosis and management of rheumatoid arthritis (RA) in Native American communities that have little or no access to rheumatology care.

7 Nov 2023

Using TNF inhibitors during pregnancy not associated with worse fetal or obstetric outcomes

According to new research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy (Abstract #0477).

7 Nov 2023

Researchers call for urgent improvement in pain management for inflammatory arthritis patients

Researchers from Keele University's School of Medicine have found that analgesic medicines - commonly known as "painkillers" - are widely prescribed to people with inflammatory arthritis across England despite little research evidence that they improve pain for these patients, and studies showing they can cause serious side-effects.

12 Oct 2023

COVID-19 associated with increased risk of developing various autoimmune diseases and risk could be attenuated by vaccination

COVID-19 can increase the risk of various autoimmune diseases; however, this risk appears to be mitigated by vaccination against COVID-19.

21 Aug 2023

A deeper look into axial spondyloarthritis: Prevalence, diagnosis, and treatment

There is a large diagnostic delay for people with axial spondyloarthritis (axSpA). In 2008, the SPACE cohort started to assess the prevalence of axSpA – and the reliability of an early diagnosis in people with chronic back pain (CBP).

31 May 2023

Long-term opioid use more common among patients with rheumatic and musculoskeletal conditions

Patients with rheumatic and musculoskeletal conditions are vulnerable to long term opioid use, with up to 1 in 3 of those with rheumatoid arthritis or fibromyalgia, who take these drugs for the first time, potentially at risk, suggest the findings of a research letter, published online in the Annals of the Rheumatic Diseases.

18 May 2023

New guideline focuses on the timing of hip and knee arthroplasty

The American College of Rheumatology and the American Association of Hip and Knee Surgeons released a summary of its new guideline titled "the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients with Symptomatic Moderate to Severe Osteoarthritis or Osteonecrosis Who Have Failed Nonoperative Therapy."

14 Mar 2023

Combination treatment does not slow radiographic spinal progression in radiographic axSpA patients

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that combining a nonsteroidal anti-inflammatory drug and TNF inhibitor did not significantly slow radiographic spinal progression in radiographic axial spondyloarthritis patients.

8 Nov 2022

Dietary components do not have impact on RMD outcomes

In 2022, EULAR - the European Alliance of Rheumatology Associations - published new recommendations regarding lifestyle behaviors and work participation to prevent progression of rheumatic and musculoskeletal diseases (RMDs).

1 Nov 2022

Study finds an increase in the proportion of adults in England diagnosed with inflammatory arthritis

The proportion of adults in England diagnosed with inflammatory arthritis has increased by at least 40% between 2004 to 2020, new Keele University research has found.

25 Oct 2022

Integrated community care approach can offer solution to struggling rheumatology services, experts say

As patients wait up to a decade for the diagnosis of life-impacting rheumatic conditions, experts argue that ingrained pressures facing NHS rheumatology services can, and should, be eased with an integrated community care/secondary care approach, rather than a reliance on secondary care alone.

3 Aug 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

27 Jun 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

27 Jun 2022

Exploring the effectiveness of various treatments in people with axial spondyloarthritis

axSpA is a chronic inflammatory rheumatic disease that mainly affects the spine and sacroiliac joints. It can cause significant pain and disability.

3 Jun 2022

Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease

Researchers investigated the longevity and intensity of the SARS-CoV-2 vaccine immune response in patients suffering from immune-mediated inflammatory diseases.

15 Apr 2022

Spondyloarthritis News and Research

Tryptophan digestion by gut microbiome spurs arthritis inflammation

Unlocking sulfasalazine's mechanism of action in IBD-SpA patients

Study shows nuanced pregnancy outcomes for pregnant individuals with autoimmune disease

Study finds no fertility decline in men with inflammatory joint disease

New training program expands access to rheumatology care for Native American communities

Using TNF inhibitors during pregnancy not associated with worse fetal or obstetric outcomes

Researchers call for urgent improvement in pain management for inflammatory arthritis patients

COVID-19 associated with increased risk of developing various autoimmune diseases and risk could be attenuated by vaccination

A deeper look into axial spondyloarthritis: Prevalence, diagnosis, and treatment

Long-term opioid use more common among patients with rheumatic and musculoskeletal conditions

New guideline focuses on the timing of hip and knee arthroplasty

Combination treatment does not slow radiographic spinal progression in radiographic axSpA patients

Dietary components do not have impact on RMD outcomes

Study finds an increase in the proportion of adults in England diagnosed with inflammatory arthritis

Integrated community care approach can offer solution to struggling rheumatology services, experts say

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

Exploring the effectiveness of various treatments in people with axial spondyloarthritis

Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News